Eitr Biologics, Inc.

Eitr Biologics, Inc., a for-profit biotechnology company headquartered in San Diego, California, develops antibody-based therapeutics and nanotherapeutics targeting viral infections and biological threats, operating as a prime contractor on federal medical countermeasure development programs and as a subrecipient on federal research grants. The company competes full-and-open, without set-aside designations on its prime awards, and holds one $315.7 million definitive contract from the Office of the Assistant Secretary for Preparedness and Response that anchors its portfolio.

Eitr's customer base concentrates heavily on federal biodefense and medical countermeasure agencies. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response dominates by potential value, holding a single $315.7 million definitive contract awarded September 22, 2023 (cost-plus-fixed-fee, completion September 30, 2034) for development of a multimodal antibody platform to extend the window of immunotherapeutic intervention, with work focused on critical evaluation of VHH (variable domain of heavy chain antibody) as a platform medical countermeasure technology. The Defense Health Agency represents the majority of award count and ongoing work: ten awards with $19.1 million combined potential value, predominantly delivery orders under a $11.5 million single-award indefinite-delivery contract (IDC HT942523D0011, completion August 14, 2028) for novel nanotherapeutics development targeting pneumonic plague caused by Yersinia pestis. Recent DHA delivery orders include a $1.86 million award (September 20, 2024, through December 31, 2025) for novel nanotherapeutics development; a $926,999 order (February 1, 2026, through December 31, 2027) for bispecific broad-spectrum nanobody development; and a $270,000 order (April 1, 2026, through March 31, 2027) for bispecific broad-spectrum nanobody therapeutics. The National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention round out the customer set, with NIAID funding Phase I Small Business Innovation Research work on bispecific nanotherapeutics as broad-spectrum influenza antivirals (award date September 30, 2023, completion March 29, 2025) and betacoronavirus medical countermeasures (award date July 1, 2023, completion August 31, 2027).

Eitr's capability portfolio centers on antibody discovery, cell sorting, and nanotherapeutic engineering. Concrete representative work includes sorting peripheral blood mononuclear cells from Lassa fever virus and Venezuelan Equine Encephalitis Virus survivors to discover and produce monoclonal antibodies for assessment in in vitro and in vivo assays (purchase order awards of $1.3 million, December 6, 2023, and $1.66 million, November 28, 2022); developing novel ODIN therapeutic medical countermeasures for pneumonic plague ($499,896, July 1, 2024); and engineering nanotherapeutic approaches targeting outer membrane proteins of Yersinia pestis ($750,000, September 1, 2023).

Activity has grown from one award in 2022 to a peak of six awards in 2023, declining to five in 2024 and three in 2025, with two awards recorded in 2026. Four awards (combined potential value $2.5 million) complete within the next twenty-four months, representing modest recompete exposure relative to the $315.7 million ASPR contract, which extends through 2034. Eitr subcontracts as a research contributor to Albert Einstein College of Medicine on the PROVIDENT federal grant program (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats), with sub-awards dated August 2024 through September 2025, and serves in a technical-expertise role under The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on USAMRIID-based research for antibody discovery and manufacturing scale-up.